Claims
- 1. A pharmaceutical composition to inhibit H-2 histamine receptors comprising a pharmaceutical carrier and in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR15## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a thiazole, isothiazole, oxazole or isoxazole ring;
- X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR16## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ;
- R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and
- R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
- 2. A pharmaceutical composition of claim 1 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-(2-thiazolylmethylthio)ethyl]guanidine.
- 3. A pharmaceutical composition of claim 1 in which the heterocyclic compound is N-cyano-N'-[2-(3-isothiazolylmethylthio)ethyl]-N"-methylguanidine.
- 4. A pharmaceutical composition of claim 1 in which the heterocyclic compound is N-cyano-N'-[2-(3-isoxazolylmethylthio)ethyl]-N"-methylguanidine.
- 5. A pharmaceutical composition of claim 1 in which the pharmaceutical composition is in the form of a tablet or capsule.
- 6. A pharmaceutical composition of claim 1 in which the heterocyclic compound is present in an amount of from about 50 mg. to about 250 mg.
- 7. A method of inhibiting H-2 histamine receptors which comprises administering to an animal in need of inhibition of said receptors in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR17## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a thiazole, isothiazole, oxazole or isoxazole ring;
- X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR18## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ;
- R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and
- R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
- 8. A method of claim 7 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-(2-thiazolylmethylthio)ethyl]guanidine.
- 9. A method of claim 7 in which the heterocyclic compound is N-cyano-N'-[2-(3-isothiazolylmethylthio)ethyl]-N"-methylguanidine.
- 10. A method of claim 7 in which the heterocyclic compound is N-cyano-N'-[2-(3-isoxazolylmethylthio)ethyl]-N"-methylguanidine.
- 11. A method of claim 7 in which the heterocyclic compound is administered orally.
- 12. A method of claim 7 in which the heterocyclic compound is administered in a daily dosage regimen of from about 150 mg. to about 1000 mg.
- 13. A method of inhibiting gastric acid secretion which comprises administering to an animal in need thereof in an effective amount to inhibit gastric acid secretion a heterocyclic compound of the formula: ##STR19## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a thiazole, isothiazole, oxazole or isoxazole ring;
- X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR20## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ;
- R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and
- R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
- 14. A method of claim 13 in which the heterocyclic compound is N-cyano-N"-methyl-N"-[2-(2-thiazolymethylthio)ethyl]guanidine.
- 15. A method of claim 13 in which the heterocyclic compound is N-cyano-N"-[2-(3-isothiazolylmethylthio)ethyl]-N"-methylguanidine.
- 16. A method of claim 13 in which the heterocyclic compound is N-cyano-N'-[2-(3-isoxazolylmethylthio)ethyl]-N"-methylguanidine.
Priority Claims (1)
Number |
Date |
Country |
Kind |
136/72 |
Feb 1972 |
EI |
|
Parent Case Info
This is a division of application Ser. No. 637,499 filed Dec. 4, 1975, now U.S. Pat No. 4,024,271, which is a division of application Ser. No. 450,957 filed Mar. 14, 1974, now U.S. Pat. No. 3,950,333, which is a continuation-in-part of Ser. No. 290,584 filed Sept. 20, 1972, now abandoned, which is a continuation-in-part of Ser. No. 230,451 filed Feb. 29, 1972, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
3838161 |
Rojappa et al. |
Sep 1974 |
|
3932443 |
White |
Jan 1976 |
|
3950353 |
Durant et al. |
Apr 1976 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
637499 |
Dec 1975 |
|
Parent |
450957 |
Mar 1974 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
290584 |
Sep 1972 |
|
Parent |
230451 |
Feb 1972 |
|